Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of the Binding Properties of Maghemite Nanoparticle Surface-Coated with Meso-2-3-Dimercaptosuccinic Acid to Serum Albumin

Full text
Author(s):
Simoni, Andreza R. [1] ; Garcia, Mnica P. [2] ; Azevedo, Ricardo B. [2] ; Chaves, Sacha Braun [2] ; Lacava, Z. G. M. [2] ; Lima, E. C. D. [3] ; Morais, P. C. [4] ; Tedesco, A. C. [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, FFCLRP USP, BR-14040901 Ribeirao Preto - Brazil
[2] Univ Brasilia, Inst Ciencias Biol, BR-70910900 Brasilia, DF - Brazil
[3] Univ Fed Goias, Inst Quim, BR-74001970 Goiania, Go - Brazil
[4] Univ Brasilia, Inst Fis Nucl Fis Aplicada, BR-70910900 Brasilia, DF - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Journal of Nanoscience and Nanotechnology; v. 8, n. 11, p. 5813-5817, NOV 2008.
Web of Science Citations: 5
Abstract

In this study the interaction between magnetic nanoparticles (MNPs) surface-coated with meso-2,3-dimercaptosuccinic acid (DMSA) with both bovine serum albumin (BSA) and human serum albumin (HSA) was investigated. The binding of the MNP-DMSA was probed by the fluorescence quenching of the BSA and HSA tryptophan residue. Magnetic resonance and light microscopy analyses were carried out in in vivo tests using female Swiss mice. The binding constants (K(b)) and the complex stoichiometries (n) indicate that MNP-DMSA/BSA and MNP-DMSA/HSA complexes have low association profiles. After five minutes following intravenous injection of MNP-DMSA into mice's blood stream we found the lung firstly target by the MNP-DMSA, followed by the liver in a latter stage. This finding suggests that the nanoparticle's DMSA-coating process probably hides the thiol group, through which albumin usually binds. This indicates that biocompatible MNP-DMSA is a very promising material system to be used as a drug delivery system (DDS), primarily for lung cancer treatment. (AU)